Xiromed debuts generic Nuvaring

Xiromed is introducing EnilloRing (etonogestrel/ethinyl estradiol vaginal ring), a generic version of Nuvaring. EnilloRing is a contraceptive vaginal ring.

“The launch of EnilloRing is an exciting milestone in Xiromed’s journey to becoming a leading generic provider of women’s healthcare products in the United States,” said Bob Spina, CEO of Xiromed. “Xiromed has established a comprehensive portfolio of women’s health pharmaceuticals, including oral contraceptives and transdermal gels. With the availability of EnilloRing, Xiromed offers an additional long-term contraceptive option to patients in the U.S. We are excited for the opportunity to continue to broaden and grow the availability of contraceptive options for U.S. patients."

[Read more: Xiromed debuts generic Rozerem]

Spina added, "EnilloRing was developed at our dedicated hormonal facility, Laboratorios Leon Pharma SAU, in Leon, Spain, where it is also manufactured. This product launch demonstrates our parent company, Insud Pharma’s dedication to investing in the development of new and complex technologies to broaden our pipeline and expand our offering of new dosage forms to our customers.”

Annual sales for Nuvaring and its generics for the 12-month period ending in July, 2023 were $528 million, per IQVIA.